Relay Therapeutics (NASDAQ:RLAY) Insider Peter Rahmer Sells 4,508 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 4,508 shares of Relay Therapeutics stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $20.03, for a total value of $90,295.24. Following the transaction, the insider owned 223,657 shares in the company, valued at $4,479,849.71. This trade represents a 1.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Peter Rahmer also recently made the following trade(s):

• On Tuesday, July 28th, Peter Rahmer sold 748 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.61, for a total transaction of $13,920.28.
• On Tuesday, June 30th, Peter Rahmer sold 50,000 shares of Relay Therapeutics stock. The stock was sold at an average price of $19.09, for a total transaction of $954,500.00.

Relay Therapeutics Price Performance

RLAY opened at $18.77 on Friday. The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of -11.96 and a beta of 1.69. The business’s 50-day moving average price is $19.27 and its two-hundred day moving average price is $14.74. Relay Therapeutics, Inc. has a 1 year low of $3.52 and a 1 year high of $21.27.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The business had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.96 million. Sell-side analysts anticipate that Relay Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RLAY shares. Citizens Jmp increased their price objective on Relay Therapeutics from $21.00 to $26.00 and gave the company a “market outperform” rating in a report on Monday, August 10th. Citigroup restated a “market outperform” rating on shares of Relay Therapeutics in a report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Monday, July 6th. The Goldman Sachs Group lifted their price objective on shares of Relay Therapeutics from $22.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Finally, Zacks Research upgraded shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.92.

Institutional Investors Weigh In On Relay Therapeutics

Institutional investors have recently made changes to their positions in the company. Torren Management LLC bought a new stake in Relay Therapeutics in the 4th quarter valued at $30,000. KBC Group NV bought a new position in Relay Therapeutics during the 1st quarter worth $34,000. Allworth Financial LP bought a new position in Relay Therapeutics during the 2nd quarter worth $34,000. Smartleaf Asset Management LLC lifted its holdings in shares of Relay Therapeutics by 288.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after buying an additional 3,287 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Relay Therapeutics in the fourth quarter valued at about $46,000. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.